1. Home
  2. Directory
  3. California
  4. Fort Bragg
  5. Pharmacist
  6. NPI Profile
  7. Prescriptions 1295035368

MS. NATALIE MARIA STEWART RPH
Prescription History 1295035368
Pharmacist in Fort Bragg, CA

NPI Status: Active since October 23, 2010

Contact Information

660 S MAIN ST
FORT BRAGG, CA
ZIP 95437
Phone: (707) 964-4058

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. NATALIE MARIA STEWART RPH, an active Pharmacist specialist practicing in Fort Bragg, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 476 documented patient claims. Among these therapy options, the most frequently utilized medication is Arexvy, which accounts for 283 claims alone.

Medication Index

A
B
S
No matching medications currently found on file.

Adacel Tdap

Generic Formulation: Diph,pertuss(Acell),tet Vac/PfSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 21
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.8
Peer Average Days Supply29
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,551.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$73.90

State Avg Cost Per Claim

$54.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This vaccine is used to keep up protection (immunity) against diphtheria, tetanus (lockjaw) and pertussis (whooping cough) in children and adults who have been vaccinated for these diseases in the past. It may also be given during the third trimester of pregnancy to help prevent pertussis in the newborn baby. Vaccination is the best way to protect against these life-threatening diseases. Vaccines work by causing the body to produce its own protection (antibodies). Booster doses are needed to keep up immunity because antibody levels may become too low over time to provide the needed protection.

Arexvy

Generic Formulation: Rsvpref3 Antigen/As01e/PfSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 283
30-Day Fills 283.0
Days Supply 283
CA State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$320.09

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Boostrix Tdap

Generic Formulation: Diphth,pertuss(Acell),tet VacSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 22
CA State Average Benchmarks
Peer Average Claims84.0
Peer Average 30-Day Fills84.4
Peer Average Days Supply108
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.8% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,519.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$69.08

State Avg Cost Per Claim

$63.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Shingrix

Generic Formulation: Varicella-Zoster Ge/As01b/PfSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 150
30-Day Fills 150.0
Days Supply 150
CA State Average Benchmarks
Peer Average Claims94.0
Peer Average 30-Day Fills95.5
Peer Average Days Supply168
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 59.6% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $32,747.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$218.31

State Avg Cost Per Claim

$196.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. NATALIE MARIA STEWART RPH provides transparency into local medical care patterns within Fort Bragg, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pharmacist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.